Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Diabetes is now a pandemic disease. Moreover, a large number of people with prediabetes are at risk for developing frank diabetes worldwide. Both type 1 and type 2 diabetes increase the risk of atherosclerotic cardiovascular disease (CVD). Even with statin treatment to lower LDL cholesterol, patients with diabetes have a high residual CVD risk. Factors mediating the residual risk are incompletely characterized. An attractive hypothesis is that remnant lipoprotein particles (RLPs), derived by lipolysis from VLDL and chylomicrons, contribute to this residual risk. RLPs constitute a heterogeneous population of lipoprotein particles, varying markedly in size and composition. Although a universally accepted definition is lacking, for the purpose of this review we define RLPs as postlipolytic partially triglyceride-depleted particles derived from chylomicrons and VLDL that are relatively enriched in cholesteryl esters and apolipoprotein (apo)E. RLPs derived from chylomicrons contain apoB48, while those derived from VLDL contain apoB100. Clarity as to the role of RLPs in CVD risk is hampered by lack of a widely accepted definition and a paucity of adequate methods for their accurate and precise quantification. New specific methods for RLP quantification would greatly improve our understanding of their biology and role in promoting atherosclerosis in diabetes and other disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“elevated plasma TG levels (with the accumulation of TRL and remnant particles) are related not only to subclinical atherosclerosis and vascular inflammation independently of LDL-C in statin-naïve, apparently healthy subjects”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At moderately elevated plasma TG levels, there is increased secretion of large TG-enriched VLDL and chylomicrons from the liver and small intestine that, when combined with suboptimal LpL action in obesity, insulin resistance, and/or diabetes mellitus, results in remnant accumulation.36”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The absence of lipolysis (i.e. complete LPL deficiency) results in the extreme elevation of large ‘nascent’ TRL without any concomitant increase in remnants;36,67,68 here, pancreatitis rather than ASCVD is the major risk.”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On a per particle basis, cholesterol-rich remnant particles are more potent inducers of macrophage foam cells than LDL and do not need structural modification to trigger uptake.36,93,141”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“but also equally to residual cardiovascular risk among statin-treated patients, especially those with diabetes mellitus.2,20,36–38”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
The Metabolic Basis of Inherited Disease
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-389_2 · Cited by 3,983
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 3×
“Furthermore, clinical trials of fibrates and n-3 fatty acids (polyunsaturated fatty acids, also often referred to as fish oils) have, with the exception of REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) and JELIS (Japan EPA Lipid Intervention Study), been mostly negative for CVD…”
BackgroundAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335 · cited 1×
“A recent new classification system of T2DM, based on different patient characteristics and risk of diabetes complications, divides adults into five different clusters of diabetes (3).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 1×
“Abundant epidemiological evidence associated triglyceride levels with CVD risk (11,12), although the risk was often attenuated when adjusted for potential confounders, such as HDL-C (13).”
BackgroundTriglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citationAtherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701 · cited 1×
“Despite decades of experimental data linking RLPs to atherogenesis in animal models and humans (70), the impact of RLPs as causal mediators in CVD associated with hypertriglyceridemia in patients with T2DM is still uncertain.”
BackgroundChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationPathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708 · cited 1×
“LDL-C concentrations are normal or only slightly elevated, but the LDL particles are characteristically small and dense with triglyceride enrichment (55).”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“A key early observation was that a null mutation in APOC3, the gene encoding apoC-III (apoC3), which acts in part by inhibiting LPL, associated with reduced triglyceride levels and reduced CVD risk in an Amish population (15).”
Background
Cited by
Items 101–200 of 229
Peng, J., Li, D., Liu, L., Xiang, Y., & Tang, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1096045 · Cited by 11
Hermans, M. P., Dierckxsens, Y., Janssens, I., Seidel, L., Albert, A., Ahn, S. A., Rousseau, M. F., & Khan, A. P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1280234 · Cited by 12
Chen, M., Chen, Z., Ye, H., Cheng, Y., Jin, Z., & Cai, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1286091 · Cited by 12
“These studies would suggest that RC is a factor in residual cardiovascular risk in addition to LDL-C (28).”
BackgroundApproach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 15
Başoğlu, Ö. K., Taşbakan, M. S., & Kayıkçıoğlu, M. (2023) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10490 · Cited by 12
Wolska, A. T., Sampson, M. L., Zubirán, R., Meeusen, J. W., Donato, L. J., Jaffe, A. S., & Remaley, A. T. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1452869 · Cited by 11
“As we have observed, LDL-TG has been strongly linked to speci fi c conditions that predispose to ASCVD, such as diabetes and obesity (34).”
BackgroundCausal associations between disorders of lipoprotein metabolism and ten cardiovascular diseases
Gao, Q., Tan, J., Fan, L., Wang, X., Hua, L., & Cai, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1023006 · Cited by 11
“In addition to these classical cardiovascular risk factors, a growing body of research has indicated that lipoproteinrelated factors account for a considerable amount of residual cardiovascular risk (Chait et al., 2020).”
BackgroundKobayashi, Y., Fujikawa, T., Haruna, A., Kawano, R., Ozawa, M., Haze, T., Komiya, S., Suzuki, S., Ohki, Y., Fujiwara, A., et al. (2023) · Medicina · doi:10.3390/medicina60010075 · Cited by 12
“RLP-C (produced by lipolysis from very-low-density lipoproteins and chylomicrons) is thought to contribute to this residual risk, although the factors mediating such a risk are not completely understood [31].”
BackgroundRemnant Cholesterol and the Risk of Coronary Artery Disease in Patients With Type 2 Diabetes
Wang, K., Ding, Y., Wang, R., Yang, J., Liu, X., Han, H., Shen, H., Sun, Y., Zhou, Y., & Ge, H. (2022) · Angiology · doi:10.1177/00033197221121008 · Cited by 11
“Because of the different lipid metabolism and increased vascular inflammation, there were still a great number of T2DM patients receiving the lipid-lowering therapy targeted at lowing LDL-C, suffering from the progression and malignant outcomes of CAD.(17,31) Researchers also found that T2DM patients under statin trea…”
BackgroundInfluentialA New Treatment Strategy for Diabetic Dyslipidemia?
Kothari, V. M., & Bornfeldt, K. (2020) · Diabetes · doi:10.2337/dbi20-0035 · Cited by 8
Self-citationLachaine, J., Charron, J.-N., Gregoire, J. C., Hegele, R. A., & Leiter, L. A. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s377935 · Cited by 7
Ko, Y., Hsu, L., Wu, S., Liao, M.-S., Teng, M., Chou, H., & Ko, Y. (2025) · Genes · doi:10.3390/genes16020157 · Cited by 9
Wang, D., Zhang, Z., Zhang, Y., Chen, S., Qu, N., Li, H., Sun, Y., Tian, X., Han, X., Wu, S., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038559 · Cited by 8
Wadop, Y. N., Bernal, R., Njamnshi, W. Y., Satizábal, C. L., Beiser, A., Ruiz, A., NJAMNSHI, A. K., Vasan, R. S., Seshadri, S. S., Himali, J. J., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13412-6 · Cited by 10
“APOE encodes the apolipoprotein E, a lipid-transport protein that plays a major role in lipid metabolism in both the periphery and the brain [38, 39].”
Jia, A., Shi, Y., Zhang, Y., Diao, Y., Chang, B., Jiang, M., Liu, W., Qiu, Z., Fu, C., & Qiu, Y. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200949 · Cited by 8
Bashir, B., Adam, S., Ho, J. H., Linn, Z., Durrington, P. N., & Soran, H. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000889 · Cited by 11
Gao, A., Liu, J., Liu, Y., Hu, C., Zhu, Y., Zhou, Y., Han, H., & Zhao, Y. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00829-6 · Cited by 6
Shao, Y., Li, Z., Wu, Q., Ye, L., & Shi, H. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07544-6 · Cited by 8
“It contains very low-density lipoprotein, intermediate-density lipoprotein, and chylomicron remnants [13].”
Xu, J. Q., Zhu, L., Xie, Y., Zhang, M., Xiao, Z., Su, R., Wen, T., & Liu, L. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230328110215 · Cited by 7
Chiu, T. H. T., Kao, Y.-C., Wang, L.-Y., Chang, H.-R., & Lin, C. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.807810 · Cited by 8
Wang, Z., Zhang, X., Qu, Y., Zhang, S., Chen, Y., Chen, X., Qi, X., Liu, P., Liu, S., Jiang, S., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01838-8 · Cited by 8
Li, T., Meng, W., Liu, T. C., Wang, Y. Z., & Zhang, M. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01936-7 · Cited by 6
Cruz‐Bautista, I., Escamilla-Núñez, C., Flores-Jurado, Y., Rojas, R., Elías-López, D., Muñoz-Hernández, L., Mehta, R., Almeda‐Valdés, P., Razo-Olvera, F. M. D., Aguilar-Salinas, C. A., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.05.002 · Cited by 8
Türkez, H., Arslan, M. E., Tatar, A. O., Tozlu, Ö. Ö., Sönmez, E., Çadırcı, K., Hacımüftüoğlu, A., CEYLAN, A. B., Açıkyıldız, M., Kahraman, Ç. Y., et al. (2022) · Materials · doi:10.3390/ma15072359 · Cited by 7
Cabodevilla, A. G., Izquierdo, M. C., Basu, D., Younis, W., Tirumalasetty, M. B., Miao, Q. R., Nasias, D., Kanter, J. E., Ho, T. W. W., Gjini, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68193-3 · Cited by 6
Self-citationLi, H., Seeßle, J., Staffer, S., Tuma‐Kellner, S., Poschet, G., Herrmann, T. R. W., & Chamulitrat, W. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149161 · Cited by 5
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70005 · Cited by 6
Ran, T., Wang, Y., Yuan, F., Liu, R., Ye, M., Zhang, M., Du, X., & Zheng, J. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02355-y · Cited by 5
“TG, TC, LDL-C, and HDL-C were assessed using a Roche Cobas 8000 analyzer, and RC was calculated as RC = TC–HDL-C–LDL-C [24].”
Yang, L., Huang, H., Wang, Z., & Xu, C. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01828-z · Cited by 6
“During the formation of atherosclerotic plaques, triglycerides are metabolized by macrophages, whereas cholesterols are not metabolized and accumulate gradually [20].”
Associations between remnant cholesterol levels and mortality in patients with diabetes
Pan, D., Xu, L., Zhang, L., Shi, D.-Z., & Guo, M. H. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i4.712 · Cited by 6
Choe, H. J., Park, S. H., Han, K., Moon, M. K., & Koo, B. K. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.11.008 · Cited by 7
Torres, L. C., & Romero, C. (2022) · Journal of Clinical Nursing · doi:10.1111/jocn.16523 · Cited by 8
Wang, W., Luo, J., Chen, Y., Liang, H., Li, Z., Chen, Y., He, J., & Liang, X. (2025) · Kidney Diseases · doi:10.1159/000545851 · Cited by 4
“TGs are primarily transported in circulation in the form of chy-lomicrons and very low-density lipoproteins (VLDLs) [9].”
Li, H., & Zhu, Z. (2025) · HORMONES · doi:10.1007/s42000-025-00737-0 · Cited by 6
“For decades, increased levels of TG and TG-rich lipoproteins have been widely recognized as risk factors for atherosclerotic cardiovascular disease [13 , 14].”
Abel, E. D., Ahima, R. S., Anderson, E. J., Berg, D. D., Berger, J. S., Das, S., Feinberg, M. W., Fisher, E. A. A., Garshick, M. S., Giannarelli, C., et al. (2026) · Circulation Research · doi:10.1161/circresaha.125.325798 · Cited by 5
Self-citationGinsberg, H. N., & Bornfeldt, K. (2026) · Circulation Research · doi:10.1161/circresaha.125.327267 · Cited by 4
Self-citationBaragetti, A. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.09 · Cited by 6
Katsanos, C. S., Tran, L., Hoffman, N., Roust, L. R., Filippis, E. D., Mandarino, L. J., Johnsson, K. A., Bëlohlávek, M., & Buras, M. R. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae727 · Cited by 5
Li, W., Liu, X., Liu, Y., Liu, J., Guo, Q., Li, J., Zheng, W., Zhang, L., Zhang, Y., Yin, H., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-74393-6 · Cited by 4
Thomsen, M. N., Skytte, M. J., Samkani, A., Weber, P., Fenger, M., Frystyk, J., Hansen, E., Holst, J. J., Madsbad, S., Magkos, F., et al. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.11.030 · Cited by 7
Jones, P. R., Rajalahti, T., Resaland, G. K., Aadland, E., Steene‐Johannessen, J., Anderssen, S. A., Bathen, T. F., Andreassen, T., Kvalheim, O. M., & Ekelund, U. (2022) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-022-01244-w · Cited by 6
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Does breakfast skipping alter the serum lipids of university students?
Solangi, S. P., Channa, N. A., Awan, A. Y., Mugheri, M. H., Soomro, Z. H., & Noorani, L. (2025) · BMC Nutrition · doi:10.1186/s40795-024-00970-7 · Cited by 3
“HDL-C functions in processes such as reverse cholesterol transport and inhibits LDL-C oxidation [25], this mechanism of HDL-C is helpful in understanding the imbalance of serum lipids in present study.”
Li, X.-X., Zhang, J.-Y., Chen, S.-Y., Wu, X., Ma, C., & Shen, H. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07871-y · Cited by 3
“This composition illustrates the dynamic alterations in lipoprotein metabolism that occur in response to dietary intake and fasting conditions [22].”
Johansen, M. Ø., Vedel‐Krogh, S., Nielsen, S. F., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120605 · Cited by 6
Yu, Y., Jiao, Y., Chang, S., Li, Y. G., Shang, K., Song, G., & Yin, C. (2026) · Journal of Health Population and Nutrition · doi:10.1186/s41043-026-01286-x · Cited by 4
Zambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Residual Cardiovascular Risk Determined through Posthoc Analysis of the REAL-CAD Trial
Endo, Y., Sasaki, K., & Ikewaki, K. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed245 · Cited by 3
Distinct lipoprotein contributions to valvular heart disease: Insights from genetic analysis
Luo, D., Björnson, E., Wang, X., Zhang, B., Xu, C., Guan, Y., Xiang, S., Borén, J., Hao, X., & Chen, J. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133218 · Cited by 3
Atherogenic dyslipidaemia: the other pandemic, associated with diabesity
Núñez-Cortés, J. M., & Pedro‐Botet, J. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.01.002 · Cited by 3
Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes
Goldberg, R. B. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.582826 · Cited by 3
“More likely hypertriglyceridemia is a marker for other metabolic abnormalities such as dysfunctional HDL, atherogenic small dense LDL and remnant lipoprotein particles, making up an atherogenic tetrad (28, 29).”
BackgroundWu, T., Chou, C., Liu, C.-C., Chen, C.-F., Cheng, C.-F., & Wang, L. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104023 · Cited by 3
Shao, Y., Feng, X., Chen, Y., Zhang, G., Liu, Y., Ht, L., Xue, D., Mei, Y., Yao, L., & Zhuang, Q. (2026) · Medicine · doi:10.1097/md.0000000000047859 · Cited by 2
“[15,16] Moreover, during the hydrolysis of triglycerides within these remnant particles, substantial amounts of free fatty acids and monoacylglycerols are released.”
Fan, X., Wang, X., She, J., Niu, X., Luo, Y., Wen, X., Zheng, T., & Wu, Y. (2023) · Journal of Investigative Medicine · doi:10.1136/jim-2022-002401 · Cited by 2
Luo, S., Yang, S., Li, P., Gu, N., Yang, D., Lu, Z., Lu, Z., Zhao, R., & Shi, B. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.010 · Cited by 3
Remnant Cholesterol—A Novel Risk Marker for Left Ventricular Remodeling and Dysfunction
Wadström, B. N., & Bahrami, H. S. Z. (2023) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.123.016110 · Cited by 2
Bays, H. E. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_26 · Cited by 1
Lewis, G. F., & Mulvihill, E. E. (2024) · Diabetes · doi:10.2337/dbi23-0036 · Cited by 1
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
Симонова, Г. И., Щербакова, Л. В., Malyutina, S. K., Каширина, А. П., & Ragino, Y. I. (2024) · Ateroscleroz · doi:10.52727/2078-256x-2024-20-3-326-344 · Cited by 1
Esmaeili, S., Fahimfar, N., Esmaeili, B., Rezaei–Tavirani, M., Razi, F., & Bandarian, F. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01692-8 · Cited by 1
Two Sides of Triglycerides in Atherogenesis: An Essential Contributor
Poznyak, A. V., Kozlov, S. G., Babayeva, G. A., Sukhorukov, V. N., & Orekhov, A. N. (2025) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468241291640 · Cited by 2
Wu, X., Wu, M., Huang, H., Liu, Z., Huang, H., & Wang, L. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1651935 · Cited by 3
Wu, D., Lan, Y., Ding, X., Balmer, L. A., Li, X., Wang, W., Wu, S., & Chen, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07028-7 · Cited by 3
Singh, A., Chauhan, B., & Singh, A. (2026) · Comparative Clinical Pathology · doi:10.1007/s00580-026-03751-9 · Cited by 1
“There are several types of lipoproteins, including chylomicrons (CM), very low density lipoprotein (VLDL), intermediate density lipoprotein, LDL, high density lipoprotein (HDL), and lipoprotein (a) [Lp (a)] (Mach et al. 2020, Chait et al. 2020).”
Boulmpou, A., Pană, M.-A., İleri, Ç., Ullah, I., Cacciatore, S., Spadafora, L., Bernardi, M., Busnatu, Ș., Biondi‐Zoccai, G., & Perone, F. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag022 · Cited by 2
Li, J., Shi, F., Huang, D., & Yue, D. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1648797 · Cited by 1
Han, G., Lei, C. L., Shi, Y., Gao, J., Liu, X., Peng, K., Cai, Y., Hoi, P. M., & Yichong, L. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101047 · Cited by 1
“…chylomi-crons and XXL-VLDL, are generally considered too large to cross the vascular wall, resulting in a comparatively lower atherogenic profile (38), while smaller RC particles may more readily penetrate the arterial wall and provoke local inflammatory responses that induce atherosclerotic…”
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 2
Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease
Davidson, N. O. (2026) · Circulation Research · doi:10.1161/circresaha.126.327269 · Cited by 2
Soflaei, S. S., Varasteh, N., Pourali, G., Azarkar, S., Ghalibaf, A. M., Mohammadi‐Bajgiran, M., Ebrahimi, M., Alimi, H., Shahri, B., Izadi‐Moud, A., et al. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0058 · Cited by 2
“41,42 This fi nding in our study was in contrast with a Korean study that announced a high TG level was not a risk factor for ischemic ECG presentations.”
Data analysis methods for evaluating cardiovascular disease in patients
Hussein, W. N., Mohammed, Z. M., & Almnaseer, Z. A. (2023) · Measurement Sensors · doi:10.1016/j.measen.2023.100674 · Cited by 1
Dislipemia aterogénica: la otra pandemia, asociada a la diabesidad
Núñez-Cortés, J. M., & Pedro‐Botet, J. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.12.001 · Cited by 3
Association of Metabolic Syndrome and Ischemic Changes in ECG: Result from a Population-Based StudyPreprint
Soflaei, S. S., Varasteh, N., Pourali, G., Azarkar, S., Ghalibaf, A. M., Mohammadi‐Bajgiran, M., Ebrahimi, M., Alimi, H., Shahri, B., Izadi‐Moud, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3052616/v1 · Cited by 1
Viljoen, A., Handhle, A., & Wierzbicki, A. S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch48 · Cited by 1
Jeong, I. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.80 · Cited by 1
Komentár k ESC/EASD 2019 Odporúčaniam pre diabetes, prediabetes a kardiovaskulárne ochorenia
Fábryová, Ľ., Martinka, E., & Murín, J. (2020) · Cardiology letters · doi:10.4149/cardiol_2020_4_1
Effect of Remnant Lipoprotein Cholesterol and Nitric Oxide in Young Coronary Heart Disease Subjects
Jaishankar, T., Shivasekar, M., Vinodhini, V. M., & Veeraragavan, S. (2021) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2021.131522
Gong, R., Tian, Y., Hu, T., Xu, Z., Deng, X., Shen, X., & Wei, X. (2021) · Research Square · doi:10.21203/rs.3.rs-793028/v1 · Cited by 1
New Agents for Treatment of Dyslipidemia
Simha, V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch17
Editorial: Diabetes Augmentation on Vascular Disease
Getz, G. S., Reardon, C. A., & Borén, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.810822
“Even with treatment of the dyslipidemia there remains a substantial risk of atherosclerotic cardiovascular disease (ASCVD), which appears to be attributable to the plasma accumulation of triglyceride rich remnant lipoproteins containing excess quantities of apoC3 produced by the diabetic liver (2).”
BackgroundFan, X., Wang, X., She, J., Niu, X., Luo, Y., Wen, X., Zheng, T., & Wu, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1385123/v1
Clinical and biochemical diagnostic methods: What do blood lipid levels tell us?
Elam, M. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00011-0
Pulipati, V. P., & Brinton, E. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00023-6
Ginsberg, H. N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00031-5
Self-citationBrinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24
Laboratory Assessment of Lipoproteins in Type 2 Diabetes
SULLIVAN, D. R. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_1
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_8
Coronary atherosclerotic plaque regression strategies
Poznyak, A. V., Yakovlev, A. А., Popov, M. A., Zhuravlev, A. D., Sukhorukov, V. N., & Orekhov, A. N. (2024) · Journal of Biomedical Research · doi:10.7555/jbr.37.20230223 · Cited by 1
RetractedLi, R., Liu, J., Han, P., Zhao, L., & Li, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4407384/v1
The Impact of Remnant Cholesterol on Cardiovascular Fitness in Young Adults: Insights from NHANESPreprint
Qin, S., Chen, J., Sun, M., & Zhang, D. (2024) · Research Square · doi:10.21203/rs.3.rs-4517007/v1
More than simply leftovers: a new link between remnant cholesterol and dementia
Saez-Calveras, N., & Ishii, M. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00133-8
Hypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Kontush, A. (2024) · Wiley eBooks · doi:10.1002/9781394158393.ch21b
Noda, Y., Kometani, M., Nomura, A., Noda, M., Oka, R., Kadono, M., & Yoneda, T. (2024) · PLOS Digital Health · doi:10.1371/journal.pdig.0000648
Research Progress on Residual Cholesterol in Cardiovascular Diseases
姚, 璐. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151109
Li, Q., Chen, H., Gao, H., Wei, X., Bian, D., Zheng, L., Wei, H., Wang, W., Wang, Y., & Deng, W. (2025) · Medicine · doi:10.1097/md.0000000000042332
Modeling the postprandial CETP-mediated lipid redistribution between chylomicrons, LDL and HDL
Jansen, M., Contini, C., Hoffmann, M. M., & Pütz, G. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100847 · Cited by 1
“Thereby, cholesterol-rich pathological TRL remnants are likely derived from VLDL in a prolonged postprandial state, which may exert endothelial damage, for example, in diabetes (40) and pre-eclampsia (41).”
Time-Restricted Eating, ANGPTL4, and Reduction in Residual Cardiovascular Risk
Gugliucci, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14197026 · Cited by 1
“TRL remnants are highly atherogenic (several times more than LDL when measured by their relative cholesterol contents), promoting inflammation and endothelial dysfunction, thereby exacerbating plaque formation and progression [55,56,58].”
Jin, Y., Wang, L., Wang, Y., & Lu, J. (2025) · Research Square · doi:10.21203/rs.3.rs-7452942/v1
Metadata
- Authors
- Chait, A., Ginsberg, H. N., Vaisar, T., Heinecke, J. W., Goldberg, I. J., & Bornfeldt, K. E.
- Affiliations
- University of Washington (US)
- Columbia University (US)
- Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington, Seattle, WA
- New York University (US)
- Corresponding author
- Bornfeldt, Karin E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-16
- Volume
- 69
- Issue
- 4
- Pages
- 508-516
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC7085249
- OpenAlex
- W3011963422
- Cited by
- 229
- References
- 72
- Citations by year
- 2026: 26 · 2025: 36 · 2024: 49 · 2023: 46 · 2022: 38 · 2021: 21 · 2020: 13
- FWCI
- 4.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL126028, R01HL127694, P01HL092969, R01HL45095, R01HL73029, P01HL128203, R01HL144558, R35HL135833)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK017047, DP3DK108209)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- remnant lipoproteins, triglyceride-rich lipoproteins, atherosclerotic cardiovascular disease, residual cardiovascular risk, prediabetes, apolipoprotein E, apolipoprotein B-48, apolipoprotein B-100, chylomicrons, VLDL, lipolysis, atherosclerosis
- MeSH terms
- Animals, Cardiovascular Diseases, Chylomicrons, Diabetes Mellitus, Type 2, Humans, Lipoproteins, Lipoproteins, VLDL, Triglycerides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.